XLO - Xilio stock jumps on Gilead Sciences license deal
2024-03-28 08:23:29 ET
Gilead Sciences ( NASDAQ: GILD ) has signed an exclusive license deal to develop and commercialize Xilio Therapeutics’ ( NASDAQ: XLO ) XTX301, an investigational tumor-activated IL-12 program with potential to treat a broad range of cancers....
Xilio stock jumps on Gilead Sciences license deal